Brian Daniel Webster Sells 15,000 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $20.27, for a total value of $304,050.00. Following the sale, the insider directly owned 364,786 shares in the company, valued at $7,394,212.22. This trade represents a 3.95% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Brian Daniel Webster also recently made the following trade(s):

• On Tuesday, February 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $25.60, for a total value of $384,000.00.
• On Thursday, January 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.80, for a total value of $342,000.00.
• On Monday, December 29th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $26.59, for a total transaction of $398,850.00.

Kestra Medical Technologies Price Performance

KMTS stock opened at $19.10 on Friday. The firm has a 50 day moving average of $23.94 and a 200-day moving average of $24.52. The firm has a market capitalization of $1.11 billion and a P/E ratio of -4.82. Kestra Medical Technologies, Ltd. has a 12 month low of $13.25 and a 12 month high of $30.00. The company has a current ratio of 7.32, a quick ratio of 5.47 and a debt-to-equity ratio of 0.15.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The firm had revenue of $24.55 million for the quarter. The business’s revenue for the quarter was up 62.7% on a year-over-year basis.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on KMTS. Piper Sandler upped their price target on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Wednesday, December 24th. Wells Fargo & Company upped their target price on Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. BTIG Research reaffirmed a “buy” rating and issued a $32.00 price target on shares of Kestra Medical Technologies in a report on Wednesday. Finally, The Goldman Sachs Group set a $24.00 price objective on Kestra Medical Technologies in a report on Friday, January 16th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $29.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Farther Finance Advisors LLC purchased a new position in shares of Kestra Medical Technologies during the fourth quarter worth approximately $31,000. Russell Investments Group Ltd. grew its holdings in shares of Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Kestra Medical Technologies during the 3rd quarter valued at $48,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Kestra Medical Technologies during the 2nd quarter valued at $54,000. Finally, BNP Paribas Financial Markets raised its position in Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares during the period.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.